A Study of a Novel Precision Medicine Approach for Obesity

Status:
RECRUITING

Trial end date:
2028-11-01

Target enrollment:

Participant gender:

This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.

PHASE4

Mayo Clinic

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
Phenomix Sciences

semaglutide